A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.
Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, Adkins DR, Naughton MJ, Rader JS, Arquette MA, Fleshman JW, Creekmore AN, Goodner SA, Wright LP, Guo Z, Ryan CE, Tao Y, Soares EM, Cai SR, Lin L, Dancey J, Rudek MA, McLeod HL, Piwnica-Worms H.
Fracasso PM, et al. Among authors: dancey j.
Cancer Chemother Pharmacol. 2011 Jun;67(6):1225-37. doi: 10.1007/s00280-010-1410-1. Epub 2010 Aug 8.
Cancer Chemother Pharmacol. 2011.
PMID: 20694727
Free PMC article.
Clinical Trial.